Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?

Sanaz N. Ghafouri; John M. Timmerman; Sarah M. Larson; Monica Mead

doi:10.1038/s41409-020-01099-4

Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?

著者: Sanaz N. Ghafouri, John M. Timmerman, Sarah M. Larson, Monica Mead - Bone Marrow Transplantation 2020 被引用: 55

Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies? | Litlas